Hypoxylon truncatum extract stimulates insulin secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly type 2, face challenges in effectively stimulating insulin secretion and managing insulin resistance, with existing hypoglycemic agents often causing hypoglycemia and having side effects, while there is a need for a safe and rapid-acting therapeutic agent that can treat both insulin-dependent and independent diabetes.
Innovation Solution
A composition and method utilizing Hypoxylon truncatum extract and its components, specifically stereoisomers of Formulae I, II, and III, or their solvates, hydrates, or physiologically acceptable salts, which stimulate insulin secretion from pancreatic beta cells, potentially offering a natural and safer alternative for diabetes treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If synthetic hypoglycemic agents (sulfonylureas, biguanides, acarbose) are used to treat diabetes, then blood glucose control is improved, but side effects including hypoglycemia and toxicity increase
Solution Approach 1:
The patent employs natural compounds from Hypoxylon truncatum that act rapidly to stimulate insulin secretion but are metabolized and eliminated quickly, avoiding cumulative toxicity. The extract provides acute glucose-lowering effect without the persistent side effects of synthetic agents, allowing for safe repeated administration.
Solution Approach 2:
The patent changes the chemical parameter from synthetic pharmaceutical compounds to natural fungal metabolites (hypoxylonols). This parameter change transforms the safety profile while maintaining efficacy, as the natural compounds stimulate insulin secretion through a different mechanism that avoids the hypoglycemic side effects associated with synthetic sulfonylureas.
2Reliability
If existing hypoglycemic agents are used to stimulate insulin secretion, then blood glucose levels are reduced, but the frequency of hypoglycemia induction increases
Solution Approach 1:
The patent converts the potential harm of excessive insulin stimulation into a benefit by using natural compounds that provide physiologically appropriate stimulation. The Hypoxylon truncatum extract stimulates insulin secretion in a controlled manner that achieves glucose lowering without triggering pathological hypoglycemia, effectively converting the risk of over-stimulation into a safe therapeutic effect.
3Object-affected harmful factors
If traditional herbal medicines are used for diabetes treatment, then safety and low toxicity are improved, but the speed of action and efficacy are reduced
Solution Approach 1:
The patent extracts and isolates the specific active compounds (hypoxylonols) from the Hypoxylon truncatum fungus. This extraction process concentrates the bioactive components that stimulate insulin secretion, transforming a slowly acting herbal remedy into a potent extract with rapid onset of action comparable to synthetic pharmaceuticals while retaining the safety profile of natural compounds.
4Adaptability or versatility
If a single therapeutic agent is developed to treat both insulin-dependent and independent diabetes, then versatility is improved, but the complexity of achieving dual efficacy increases
Solution Approach 1:
The patent identifies compounds from Hypoxylon truncatum that exhibit universal activity across both type 1 and type 2 diabetes. The hypoxylonols stimulate insulin secretion in a manner that benefits insulin-deficient states (type 1) while also improving insulin sensitivity and secretion in insulin-resistant states (type 2), providing a single agent with broad applicability without requiring complex formulation adjustments.
Data Source
AI summary
Provided are a composition for stimulating insulin secretion from cells, the composition including a Hypoxylon truncatum extract or an active ingredient thereof, and a method of stimulating insulin secretion from cells.